Skip to content

Bioavailability of Hydroxytyrosol From Olive Watery Extract Supplements

Bioavailability of Hydroxytyrosol From Two Olive Watery Extract Supplements and Their Effects on Lipid Peroxidation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04876261
Enrollment
13
Registered
2021-05-06
Start date
2021-05-10
Completion date
2021-07-02
Last updated
2021-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biological Availability

Keywords

Olives

Brief summary

The aim of this cross-over study is to assess the bioavailability of hydroxytyrosol in healthy males after the intake of two olive watery extract supplements and one olive oil. Blood and urine samples will be collected before and after intake of the investigational products. Sample will be analysed regarding the level of hydroxytyrosol and preventing lipid peroxidation.

Detailed description

Background: Hydroxytyrosol is a phenolic phytochemical naturally occurring in olives with potential antioxidant, anti-inflammatory, and health benefits mainly related with cardiovascular diseases \[for review see Covas et al., 2015\]. OliPhenolia® bitter and OliPhenolia® are two food supplements resulting from the liquid by-product generated during olive oil production, that are rich in olive polyphenols, mainly hydroxytyrosol. Hydroxytyrosol and its derivatives (tyrosol and oleuropein) are present in higher levels in the watery extracts from olives when compared with the oil fraction. Most studies on hydroxytyrosol bioavailability have been performed by consuming it with olive oil or as a highly purified molecule. In a study by D'Angelo and collaborators \[D'Angelo et al, 2001\] it was shown that hydroxytyrosol can be rapidly absorbed from the blood and distributed in the human body, metabolized and eliminated rapidly in urine mainly as a glucuronide. It has been estimated that the absorption process depends on the composition of the food matrix through which hydroxytyrosol is administered \[Visioli et al, 2003\], when consumed together with fats (e.g. olive oil) it is absorbed in a greater extent. By being a water-soluble molecule, hydroxytyrosol is only slightly soluble in fats, therefore naturally present in significantly higher concentrations in the olive fruit aqueous fractions than in the olive oil. Overall, the human studies support the need to evaluate the bioavailability of hydroxytyrosol following its administration as a major component of the two aqueous food supplements, OliPhenolia® and OliPhenolia® bitter. Study Procedure: After detailed information and signed informed consent all males meeting the inclusion and exclusion criteria will be included into the study. During their study participation, participants are not allowed to consume any products with or made from olives or olive oil as well as alcohol and supplements with hydroxytyrosol, vitamins, minerals and antioxidants. Products high in polyphenols and antioxidants may only be consumed in moderate amounts. Three days prior to and at each intervention day, volunteers will be requested to avoid moderate or intense physical activity. After a run-in period, participants will return in a fasted state to the site for the first intervention visit. Volunteers will be asked to empty their bladder at home 2h before IP intake. After arriving at the site, a baseline blood and urine sample (-5 min) will be collected and the participants receive according to the individual allocation determining the sequence of the IP intake either one of the olive watery extract supplements (OliPhenolia® bitter or OliPhenolia®) or the olive oil first. Further blood and urine samples will follow (+30 min, +60 min, +90 min, +120 min, +240 min, +12 h). Vital signs and AEs will be checked throughout the intervention visit. Participants will receive several snacks and water during their visit. After a one-week washout phase each, participants will return to their second and third intervention visit. The same procedures as on intervention visit 1 will take place except the IP intake will vary according to the individual allocation. At the end of the third intervention visit, participants will receive a study compensation.

Interventions

DIETARY_SUPPLEMENTOliphenolia® bitter

* ingredients: concentrated watery extract of olives 94%, lemon juice 6% * 35 mg hydroxytyrosol, 0,24 mg Oleuropein

DIETARY_SUPPLEMENTOliphenolia®

* ingredients: grape juice concentrate 70%, concentrated watery extract of olives 30% * 38 mg hydroxytyrosol, 0,28 mg Oleuropein

DIETARY_SUPPLEMENTLa Vialla Extra Virgin Olive Oil containing 5 mg hydroxytyrosol

* extra virgin olive oil * 5 mg hydroxytyrosol

Sponsors

ISTITUTO KURZ ITALIA S.R.L.
CollaboratorUNKNOWN
Institut Kurz GmbH
CollaboratorUNKNOWN
Fattoria La Vialla di Gianni, Antonio e Bandino Lo Franco Soc. Agr. Sempl.
CollaboratorUNKNOWN
Daacro
Lead SponsorNETWORK

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Participants and the laboratory will be blinded. Laboratory staff will be unblinded after samples are being analysed. Participants will be unblinded after study end.

Intervention model description

Three-armed study with a cross-over design. Participants will be randomly assigned to either group A, B or C. The group allocation will define the sequence of product intake: * Group A: first OliPhenolia® bitter, second OliPhenolia®, third La Vialla Extra Virgin Olive Oil * Group B: first OliPhenolia®, second La Vialla Extra Virgin Olive Oil, third OliPhenolia® bitter * Group C: first La Vialla Extra Virgin Olive Oil, second OliPhenolia® bitter, third OliPhenolia®

Eligibility

Sex/Gender
MALE
Age
21 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Self-reported healthy men aged 21-50, * subject has an adequate understanding of the study and signs the informed consent to participate in the study, * willingness to follow dietary and physical activity restrictions during study participation, * body mass index range: \>18.5 and \<29.9 kg/m2.

Exclusion criteria

* Any known allergies to IPs (olives and their derivates), * any acute and chronic diseases (e.g. diagnosis of diabetes mellitus, hypertension, dyslipidemia or other cardiometabolic disorders, diagnosed hepatic, renal, or cardiovascular disease), * any kind of eating disorders, * not fluent in German, * any previous (last 14 days prior to screening) and any ongoing pharmacological therapy (e.g. any medication, vaccination, infusion), * any intake of nutritional supplements, * any known addiction to drugs and/or alcohol, * smoker, * Investigator or physician doubts truthfulness of self-reported health information.

Design outcomes

Primary

MeasureTime frameDescription
Bioavailability of hydroxytyrosol in urine-2 hrs to IP intake, 0 to 30 min, 30 to 60 min, 60 to 90 min, 90 to 120 min, 120 to 240 min and +4h to +12hThe primary objective is the bioavailability of hydroxytyrosol and its derivatives from both food supplements (OliPhenolia® bitter and OliPhenolia®) in urine when compared to extra virgin olive oil.
Bioavailability of hydroxytyrosol in blood5 min. before IP intake, 30, 60, 90, 120, 240 min and 12 hThe primary objective is the bioavailability of hydroxytyrosol and its derivatives from both food supplements (OliPhenolia® bitter and OliPhenolia®) in urine when compared to extra virgin olive oil.

Secondary

MeasureTime frameDescription
Oxidative damages to lipids in blood5 min. before IP intake, 30, 60, 90, 120, 240 min and 12 hThe secondary outcome is the measurement of the oxidized LDL(low-density lipoprotein) in blood
changes in F2alpha-isoprostanes in urine-2 hrs to IP intake, 0 to 30 min, 30 to 60 min, 60 to 90 min, 90 to 120 min, 120 to 240 min and +4h to +12hThe secondary outcome is the measurement of changes in F2alpha-isoprostanes in urine.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026